## Crohn's Disease Ulcerative Colitis (drugs S-Z)

(Simponi®, Stelara®)



Patient Information		riber + Shipping Inform	ation	
Patient name: DOB:		riber name:		
Sex: ☐ Female ☐ M	ale SSN: NPI:			
Language:		ess:		
Address:			State: Zip: _	
Apt/Suite: Cit			' '	
		a: 	Alternate:	
			, mornato.	
		 :		
Insurance plan: Plan ID:  Please fax a copy of front and back of the insurance card(s).		oping to prescriber:   First	t Fill   Always Never	
.,				
Clinical Information (Please fax all pertinent clinical and lab information)  Crohn's Disease:   K50.0 (Crohn's Disease of the Small Intenstine)				
□ K50.8 (Crohn's Disease of the Small Intenstine) □ K50.8 (Crohn's Disease of the Small Intenstine) □ K50.9 (Crohn's Disease, unspecified)				
Ulcerative Colitis: ☐ K51.0 (Ulcerative Pancolitis) ☐ K51.2 (Ulcerative Procolitis) ☐ K51.3 (Ulcerative Rectosigmoiditis)				
□ K51.5 (Left Sided Colitis) □ K51.8 (Other Ulcerative Colitis) □ K51.9 (Ulcerative Colitis, unspecified)				
			(Croordario Contro, arropoetrio	· • /
Diagnosis Date:		Date:		
Prior Therapy		Approximate S	Start Date   Approximate End	l Date
Comorbidities:				
Concomitant Medica				
Allergies:   NKDA  Other:				
Prescription				
•	imzia <sup>®</sup> and Humira <sup>®</sup> are available on the Crohn's Disea	se/Ulcerative Colitis En	_	
§ C			rollment Form A-R §  ☐ SmartJect® Autoinjector	0
•	imzia® and Humira® are available on the Crohn's Disea		_	0
§ C			☐ SmartJect® Autoinjector☐ PFS	0
§ C			□ SmartJect® Autoinjector □ PFS □ SmartJect® Autoinjector	0
§ C	☐ Inject 200 mg subcut at week 0, then 100 mg at week ☐ Inject 100 mg subcut every 4 weeks	2 3 x 100 mg/mL	☐ SmartJect® Autoinjector☐ PFS	0
§ C	☐ Inject 200 mg subcut at week 0, then 100 mg at week ☐ Inject 100 mg subcut every 4 weeks ☐ Infuse 260 mg intravenously over no less than one	2 3 x 100 mg/mL 1 x 100 mg/mL	□ SmartJect® Autoinjector □ PFS □ SmartJect® Autoinjector	0
§ C	<ul> <li>□ Inject 200 mg subcut at week 0, then 100 mg at week</li> <li>□ Inject 100 mg subcut every 4 weeks</li> <li>□ Infuse 260 mg intravenously over no less than one hour (≤55kg)</li> </ul>	2 3 x 100 mg/mL	□ SmartJect® Autoinjector □ PFS □ SmartJect® Autoinjector	
§ C	<ul> <li>□ Inject 200 mg subcut at week 0, then 100 mg at week</li> <li>□ Inject 100 mg subcut every 4 weeks</li> <li>□ Infuse 260 mg intravenously over no less than one hour (≤55kg)</li> <li>□ Infuse 390 mg intravenously over no less than one</li> </ul>	2 3 x 100 mg/mL 1 x 100 mg/mL	□ SmartJect® Autoinjector □ PFS □ SmartJect® Autoinjector □ PFS	0
§ Coolimponi® (golimumab)	<ul> <li>□ Inject 200 mg subcut at week 0, then 100 mg at week</li> <li>□ Inject 100 mg subcut every 4 weeks</li> <li>□ Infuse 260 mg intravenously over no less than one hour (≤55kg)</li> <li>□ Infuse 390 mg intravenously over no less than one hour (&gt;55 kg to &lt;85 kg)</li> </ul>	2  3 x 100 mg/mL 1 x 100 mg/mL 2 x 130 mg/26 mL	□ SmartJect® Autoinjector □ PFS □ SmartJect® Autoinjector □ PFS	
§ Coolimponi® (golimumab)	<ul> <li>□ Inject 200 mg subcut at week 0, then 100 mg at week</li> <li>□ Inject 100 mg subcut every 4 weeks</li> <li>□ Infuse 260 mg intravenously over no less than one hour (≤55kg)</li> <li>□ Infuse 390 mg intravenously over no less than one hour (&gt;55 kg to &lt;85 kg)</li> <li>□ Infuse 520 mg intravenously over no less than one</li> </ul>	2  3 x 100 mg/mL 1 x 100 mg/mL 2 x 130 mg/26 mL	□ SmartJect® Autoinjector □ PFS □ SmartJect® Autoinjector □ PFS	
§ Coolimponi® (golimumab)	<ul> <li>□ Inject 200 mg subcut at week 0, then 100 mg at week</li> <li>□ Inject 100 mg subcut every 4 weeks</li> <li>□ Infuse 260 mg intravenously over no less than one hour (≤55kg)</li> <li>□ Infuse 390 mg intravenously over no less than one hour (&gt;55 kg to &lt;85 kg)</li> <li>□ Infuse 520 mg intravenously over no less than one hour (&gt;85 kg)</li> </ul>	2	□ SmartJect® Autoinjector □ PFS □ SmartJect® Autoinjector □ PFS	
§ Coolimponi® (golimumab)	<ul> <li>□ Inject 200 mg subcut at week 0, then 100 mg at week</li> <li>□ Inject 100 mg subcut every 4 weeks</li> <li>□ Infuse 260 mg intravenously over no less than one hour (≤55kg)</li> <li>□ Infuse 390 mg intravenously over no less than one hour (&gt;55 kg to &lt;85 kg)</li> <li>□ Infuse 520 mg intravenously over no less than one hour (&gt;85 kg)</li> <li>□ Inject 90 mg subcut 8 weeks following initial</li> </ul>	2	□ SmartJect® Autoinjector □ PFS □ SmartJect® Autoinjector □ PFS	
§ Coolimponi® (golimumab)	<ul> <li>□ Inject 200 mg subcut at week 0, then 100 mg at week</li> <li>□ Inject 100 mg subcut every 4 weeks</li> <li>□ Infuse 260 mg intravenously over no less than one hour (≤55kg)</li> <li>□ Infuse 390 mg intravenously over no less than one hour (&gt;55 kg to &lt;85 kg)</li> <li>□ Infuse 520 mg intravenously over no less than one hour (&gt;85 kg)</li> </ul>	2	□ SmartJect® Autoinjector □ PFS □ SmartJect® Autoinjector □ PFS □ Vials	
§ Coolimponi® (golimumab)	<ul> <li>□ Inject 200 mg subcut at week 0, then 100 mg at week</li> <li>□ Inject 100 mg subcut every 4 weeks</li> <li>□ Infuse 260 mg intravenously over no less than one hour (≤55kg)</li> <li>□ Infuse 390 mg intravenously over no less than one hour (&gt;55 kg to &lt;85 kg)</li> <li>□ Infuse 520 mg intravenously over no less than one hour (&gt;85 kg)</li> <li>□ Inject 90 mg subcut 8 weeks following initial</li> </ul>	2	□ SmartJect® Autoinjector □ PFS □ SmartJect® Autoinjector □ PFS □ Vials	
§ Coolimponi® (golimumab)	<ul> <li>□ Inject 200 mg subcut at week 0, then 100 mg at week</li> <li>□ Inject 100 mg subcut every 4 weeks</li> <li>□ Infuse 260 mg intravenously over no less than one hour (≤55kg)</li> <li>□ Infuse 390 mg intravenously over no less than one hour (&gt;55 kg to &lt;85 kg)</li> <li>□ Infuse 520 mg intravenously over no less than one hour (&gt;85 kg)</li> <li>□ Inject 90 mg subcut 8 weeks following initial intravenous dose, then every 8 weeks thereafter</li> <li>Patient eligible for self-administration: □ Yes □ No</li> </ul>	2	□ SmartJect® Autoinjector □ PFS □ SmartJect® Autoinjector □ PFS □ Vials	
§ Calling Simponi® (golimumab)  Stelara® (ustekinumab)	<ul> <li>□ Inject 200 mg subcut at week 0, then 100 mg at week</li> <li>□ Inject 100 mg subcut every 4 weeks</li> <li>□ Infuse 260 mg intravenously over no less than one hour (≤55kg)</li> <li>□ Infuse 390 mg intravenously over no less than one hour (&gt;55 kg to &lt;85 kg)</li> <li>□ Infuse 520 mg intravenously over no less than one hour (&gt;85 kg)</li> <li>□ Inject 90 mg subcut 8 weeks following initial intravenous dose, then every 8 weeks thereafter</li> <li>Patient eligible for self-administration: □ Yes □ No</li> <li>Date of last infusion:</li></ul>	2	□ SmartJect® Autoinjector □ PFS □ SmartJect® Autoinjector □ PFS □ Vials	
§ Calling Simponi® (golimumab)  Stelara® (ustekinumab)	<ul> <li>□ Inject 200 mg subcut at week 0, then 100 mg at week</li> <li>□ Inject 100 mg subcut every 4 weeks</li> <li>□ Infuse 260 mg intravenously over no less than one hour (≤55kg)</li> <li>□ Infuse 390 mg intravenously over no less than one hour (&gt;55 kg to &lt;85 kg)</li> <li>□ Infuse 520 mg intravenously over no less than one hour (&gt;85 kg)</li> <li>□ Inject 90 mg subcut 8 weeks following initial intravenous dose, then every 8 weeks thereafter</li> <li>Patient eligible for self-administration: □ Yes □ No</li> <li>Date of last infusion:</li></ul>	2	□ SmartJect® Autoinjector □ PFS □ SmartJect® Autoinjector □ PFS □ Vials	
Simponi® (golimumab)  Stelara® (ustekinumab)	□ Inject 200 mg subcut at week 0, then 100 mg at week □ Inject 100 mg subcut every 4 weeks □ Infuse 260 mg intravenously over no less than one hour (≤55kg) □ Infuse 390 mg intravenously over no less than one hour (>55 kg to <85 kg) □ Infuse 520 mg intravenously over no less than one hour (>85 kg) □ Inject 90 mg subcut 8 weeks following initial intravenous dose, then every 8 weeks thereafter  Patient eligible for self-administration: □ Yes □ No  Date of last infusion: □  rovided by: □ Physician's Office □ Pharmacy □ 0	2	□ SmartJect® Autoinjector □ PFS □ SmartJect® Autoinjector □ PFS □ Vials □ PFS	
Simponi® (golimumab)  Stelara® (ustekinumab)	<ul> <li>□ Inject 200 mg subcut at week 0, then 100 mg at week</li> <li>□ Inject 100 mg subcut every 4 weeks</li> <li>□ Infuse 260 mg intravenously over no less than one hour (≤55kg)</li> <li>□ Infuse 390 mg intravenously over no less than one hour (&gt;55 kg to &lt;85 kg)</li> <li>□ Infuse 520 mg intravenously over no less than one hour (&gt;85 kg)</li> <li>□ Inject 90 mg subcut 8 weeks following initial intravenous dose, then every 8 weeks thereafter</li> <li>Patient eligible for self-administration: □ Yes □ No</li> <li>Date of last infusion:</li></ul>	2	□ SmartJect® Autoinjector □ PFS □ SmartJect® Autoinjector □ PFS □ Vials □ PFS	
Simponi® (golimumab)  Stelara® (ustekinumab)	□ Inject 200 mg subcut at week 0, then 100 mg at week □ Inject 100 mg subcut every 4 weeks □ Infuse 260 mg intravenously over no less than one hour (≤55kg) □ Infuse 390 mg intravenously over no less than one hour (>55 kg to <85 kg) □ Infuse 520 mg intravenously over no less than one hour (>85 kg) □ Inject 90 mg subcut 8 weeks following initial intravenous dose, then every 8 weeks thereafter  Patient eligible for self-administration: □ Yes □ No  Date of last infusion: □  rovided by: □ Physician's Office □ Pharmacy □ 0	2	□ SmartJect® Autoinjector □ PFS □ SmartJect® Autoinjector □ PFS □ Vials □ PFS	
Simponi® (golimumab)  Stelara® (ustekinumab)	□ Inject 200 mg subcut at week 0, then 100 mg at week □ Inject 100 mg subcut every 4 weeks □ Infuse 260 mg intravenously over no less than one hour (≤55kg) □ Infuse 390 mg intravenously over no less than one hour (>55 kg to <85 kg) □ Infuse 520 mg intravenously over no less than one hour (>85 kg) □ Inject 90 mg subcut 8 weeks following initial intravenous dose, then every 8 weeks thereafter  Patient eligible for self-administration: □ Yes □ No Date of last infusion: □ Tovided by: □ Physician's Office □ Pharmacy □ Cow, prescriptions will be dispensed as generic, if applicable	2	□ SmartJect® Autoinjector □ PFS □ SmartJect® Autoinjector □ PFS □ Vials □ PFS	

Confidentiality Statement: This message is intended only for the individual or entity to which it is addressed. It may contain information which may be proprietary and confidential. It may also contain privileged, confidential information which is exempt from disclosure under applicable laws, including the Health Insurance Portability and Accountability Act (HIPAA). If you are not the intended recipient, please note that you are strictly prohibited from disseminating or distributing this information (other than to the intended recipient) or copying this information. If you received this communication in error, please notify the sender immediately by calling 855-611-3399 or by emailing specialty@thriftywhite.com to obtain instructions as to the proper destruction of the transmitted material. Thank you.